| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P411997-100μg |
100μg |
现货  |
| |
| P411997-1mg |
1mg |
现货 |
| |
| P411997-5mg |
5mg |
现货 |
| |
| P411997-10mg |
10mg |
期货 |
|
| 产品名称 | Pembrolizumab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体 |
|---|---|
| 别名 | 帕博利珠单抗(抗 PD-1) |
| 英文别名 | 1374853-91-4 | 1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2-methyltetradecyl)amino]tetradecan-2-ol;3-[[(8E,10E)-2-methylhexadeca-8,10-dienyl]-[(9E,11E)-2-methylhexadeca-9,11-dienyl]amino]propane-1-thiol |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | PDCD1 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 程序性细胞死亡 1 (CD279) 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG4SP |
| 轻链亚型 | kappa |
| SDS-PAGE | 146 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1374853-91-4 |
| 分子类型 | 抗体 |
Pembrolizumab (anti-PD-1) (P411997) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Pembrolizumab (anti-PD-1) (P411997). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Pembrolizumab (anti-PD-1) (P411997) - SEC
The purity of Pembrolizumab (anti-PD-1) (P411997) is more than 95% verified by HPLC.
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ23F0900991 |
分析证书 | 25-06-24 | P411997 |
| ZJ25F0318908 |
分析证书 | 25-03-06 | P411997 |
| ZJ25F0318907 |
分析证书 | 25-03-06 | P411997 |
| ZJ25F0318906 |
分析证书 | 25-03-06 | P411997 |
| ZJ24F0707872 |
分析证书 | 24-07-05 | P411997 |
| ZJ23F0900990 |
分析证书 | 23-09-11 | P411997 |
¥455.92
¥669.90
¥669.90
¥379.90
¥159.92
¥263.92
¥559.90
¥575.92
¥463.92
¥535.92
¥329.90
¥167.92
¥339.90
¥431.92
¥669.90
¥579.90
¥559.90
¥959.90
¥269.90
¥295.92
| 1. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer.. Discov Med, 14 (77): (229-36). [PMID:23114578] [10.1021/op500134e] |
| 2. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy.. Blood, 121 (5): (734-44). [PMID:23223433] [10.1021/op500134e] |
| 3. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.. Curr Oncol Rep, 15 (2): (98-104). [PMID:23263823] [10.1021/op500134e] |
| 4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.. N Engl J Med, 369 (2): (134-44). [PMID:23724846] [10.1021/op500134e] |
| 5. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP et al.. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.. N Engl J Med, 374 (26): (2542-52). [PMID:27093365] [10.1021/op500134e] |
| 6. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A et al.. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.. N Engl J Med, 379 (21): (2040-2051). [PMID:30280635] [10.1021/op500134e] |
| 7. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B et al.. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.. N Engl J Med, 380 (12): (1116-1127). [PMID:30779529] [10.1021/op500134e] |
| 8. Saada-Bouzid E, Peyrade F, Guigay J. (2019) Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.. Curr Opin Oncol, 31 (3): (146-151). [PMID:30893146] [10.1021/op500134e] |
首页
400-620-6333
